Liver fibrosis markers in alcoholic liver disease

Table 1 Characteristic of studies concerning alcoholic liver disease

Study	Number of patients	Age (yr)	Alcohol consumption	Exclusion criteria
Rosenberg et al[24] (2004)	64	18-74	No data	Any disorder associated with extrahepatic fibrosis; cardiovascular disease or cancer; advanced cirrhosis; regular consumption of aspirin; hepatocellular carcinoma or drug-induced liver disease
Calès et al[20] (2005)	95	18-74	≥ 50 g/d for the previous 5 yr (mean: 94 g/d ± 50)	Other causes of LD or complicated cirrhosis or received antifibrotic treatment within the previous 6 mo
Naveau et al[4] (2005)	221	47 (SE = 0.7)	at least 50 g/d over the previous year	Concomitant liver disease, HIV antibodies, immune-suppression, hepatic surface antigen, antibodies to HCV, associated severe diseases
Naveau et al[22] (2009)	218	47.1 (SE = 0.7)	≥ 50 g/d during the preceding y (mean 146 g/d, SE = 80 g/d for 17 yr)	Concomitant liver disease, human immunodeficiency virus antibodies, immunosupression
Poynard et al[23] (2012)	218	47 (SD = 10.3)	No data	HIV co-infection

HCV: Hepatitis C virus; LD: Liver disease; HIV: Human immunodeficiency virus.

Table 2 Area under the curves receiver operating characteristic for the diagnosis of fibrosis in patients with alcoholic liver disease

Test	F2-F4 vs F0-F1	F4 vs F0-F3
FibroTest[22]	0.83 (95%CI: 0.77-0.88)	0.94 (95%CI: 0.90-0.96)
FibrometerA[22]	0.83 (95%CI: 0.77-0.87)	0.94 (95%CI: 0.90-0.97)
Hepascore[22]	0.83 (95%CI: 0.77-0.88)	0.92 (95%CI: 0.87-0.97)
Forns[22]	0.38 (95%CI: 0.30-0.46)	0.38 (95%CI: 0.27-0.47)
APRI[22]	0.59 (95%CI: 0.51-0.67)	0.67 (95%CI: 0.59-0.75)
FIB4[22]	0.70 (95%CI: 0.62-0.76)	0.80 (95%CI: 0.72-0.86)
FibroTest[4]	0.84 ± 0.03 (SD)	0.95 ± 0.01 (SD)
Hyaluronic acid[4]	0.79 ± 0.03 (SD)	0.93 ± 0.02 (SD)
The algorithm combining PI, α-2 macroglobulin and hyaluronic acid[20]	0.962 ± 0.018 (SD)